Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.

Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.

Liede A, Karlan BY, Narod SA.

J Clin Oncol. 2004 Feb 15;22(4):735-42. Review.

PMID:
14966099
2.
3.

Counseling for male BRCA mutation carriers: a review.

Mohamad HB, Apffelstaedt JP.

Breast. 2008 Oct;17(5):441-50. doi: 10.1016/j.breast.2008.05.001. Epub 2008 Jul 26. Review.

PMID:
18657973
4.

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

Rebbeck TR, Kauff ND, Domchek SM.

J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.

5.

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.

Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA.

J Natl Cancer Inst. 2006 Dec 6;98(23):1694-706.

PMID:
17148771
6.

Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics.

Scott CL, Jenkins MA, Southey MC, Davis TA, Leary JA, Easton DF, Phillips KA, Hopper JL.

Hum Genet. 2003 May;112(5-6):542-51. Epub 2003 Feb 25.

PMID:
12601471
7.

Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.

Simchoni S, Friedman E, Kaufman B, Gershoni-Baruch R, Orr-Urtreger A, Kedar-Barnes I, Shiri-Sverdlov R, Dagan E, Tsabari S, Shohat M, Catane R, King MC, Lahad A, Levy-Lahad E.

Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3770-4. Epub 2006 Feb 28.

8.

The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.

Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A, Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San Román C, Antoniou AC, Urioste M, Benítez J.

Clin Cancer Res. 2008 May 1;14(9):2861-9. doi: 10.1158/1078-0432.CCR-07-4436.

9.

Cancer Incidence in BRCA1 mutation carriers.

Thompson D, Easton DF; Breast Cancer Linkage Consortium..

J Natl Cancer Inst. 2002 Sep 18;94(18):1358-65.

PMID:
12237281
10.

Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.

Vicus D, Finch A, Rosen B, Fan I, Bradley L, Cass I, Sun P, Karlan B, McLaughlin J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group..

Gynecol Oncol. 2010 Aug 1;118(2):155-9. doi: 10.1016/j.ygyno.2010.03.009. Epub 2010 May 10.

PMID:
20452659
11.

Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.

Walker LC, Waddell N, Ten Haaf A; kConFab Investigators., Grimmond S, Spurdle AB.

Breast Cancer Res Treat. 2008 Nov;112(2):229-36. Epub 2007 Dec 20.

PMID:
18095154
12.

Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic.

Brooks GA, Stopfer JE, Erlichman J, Davidson R, Nathanson KL, Domchek SM.

Cancer Biol Ther. 2006 Sep;5(9):1098-102. Epub 2006 Sep 11.

PMID:
16931905
13.

BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.

Antoniou AC, Durocher F, Smith P, Simard J, Easton DF; INHERIT BRCAs program members..

Breast Cancer Res. 2006;8(1):R3. Epub 2005 Dec 12.

14.

Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.

Finch A, Metcalfe K, Lui J, Springate C, Demsky R, Armel S, Rosen B, Murphy J, Elit L, Sun P, Narod S.

Clin Genet. 2009 Mar;75(3):220-4.

PMID:
19263514
15.

Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Jernström H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P, Narod SA.

J Natl Cancer Inst. 2004 Jul 21;96(14):1094-8.

PMID:
15265971
16.

BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.

Soegaard M, Kjaer SK, Cox M, Wozniak E, Høgdall E, Høgdall C, Blaakaer J, Jacobs IJ, Gayther SA, Ramus SJ.

Clin Cancer Res. 2008 Jun 15;14(12):3761-7. doi: 10.1158/1078-0432.CCR-07-4806.

17.

BRCA2: a genetic risk factor for breast cancer.

Schwab M, Claas A, Savelyeva L.

Cancer Lett. 2002 Jan 10;175(1):1-8. Review.

PMID:
11734330
18.

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.

Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D, Tonin PN.

BMC Cancer. 2008 Apr 10;8:96. doi: 10.1186/1471-2407-8-96.

19.

Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.

Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.; Australian Ovarian Cancer Study Management Group..

J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28.

PMID:
18957670
20.

Breast cancer and ovarian cancer genetics.

Edlich RF, Winters KL, Lin KY.

J Long Term Eff Med Implants. 2005;15(5):533-45. Review.

PMID:
16218901

Supplemental Content

Support Center